ProMIS Neurosciences, Inc.
PMN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $9,797 | $8,750 | $5,464 | $4,325 |
| G&A Expenses | $0 | $1,435 | $1,996 | $0 |
| SG&A Expenses | $1,953 | $1,435 | $1,996 | $1,678 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $11,750 | $10,185 | $7,460 | $6,002 |
| Operating Income | -$11,750 | -$10,185 | -$7,460 | -$6,002 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $170 | $68 | $112 | $5,764 |
| Pre-Tax Income | -$11,580 | -$10,117 | -$7,348 | -$238 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11,580 | -$10,117 | -$7,348 | -$238 |
| % Margin | – | – | – | – |
| EPS | -6 | -7.25 | -5.25 | -0.245 |
| % Growth | 17.2% | -38.1% | -2,042.9% | – |
| EPS Diluted | -6 | -7.25 | -5.25 | -0.245 |
| Weighted Avg Shares Out | 1,394 | 1,394 | 1,394 | 1,393 |
| Weighted Avg Shares Out Dil | 1,394 | 1,394 | 1,394 | 1,393 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$11,580 | -$10,117 | -$7,348 | -$238 |
| % Margin | – | – | – | – |